康方生物（09926.HK）今日盘中大涨5.33%，截至发稿，股价报177港元。该公司股价上涨主要受到三方面利好消息推动：中期业绩增长、重要临床试验取得突破性进展以及券商上调目标价。
根据康方生物最新公布的2025年上半年业绩报告，公司实现总收入14.12亿元人民币，同比增长37.75%。其中，商业销售收入达14.02亿元，同比大幅增长49.20%。这一增长主要得益于公司两款核心产品开坦尼（卡度尼利）和依达方（依沃西）首次纳入国家医保目录后的销售增长，以及新获批一线适应症带来的贡献。
此外，康方生物宣布其重磅产品依沃西单抗（AK112）在EGFR-TKI治疗进展的局部晚期或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的III期HARMONi-A研究中达到总生存期（OS）临床终点，展现出具有统计学和临床意义的OS获益。这一突破性进展大大提升了市场对该产品前景的信心。受此影响，中金公司发布研报维持康方生物"跑赢行业"评级，并大幅上调目标价87.5%至225.00港元，进一步刺激了投资者的买入热情。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.